Illumina, Inc. (ILMN) Launches BioInsight Platform With DRAGEN v4.6

Moderna (MRNA) shares fell 20% after leaked trial data for its melanoma vaccine, despite analysts calling results 'strong.' The drop may signal the end of its 700% year-to-date rally. Merck (MRK), partnering on the vaccine, saw minimal impact. Analysts expect Merck to report strong earnings. BioNTech (BNTX) and Illumina (ILMN) are also mentioned.

Illumina established a $1.0 billion unsecured commercial paper program for general corporate purposes. The program allows short-term notes with maturities up to 397 days. A national bank will serve as the issuing and paying agent, with three dealers initially participating. No notes were outstanding as of the filing date.

Illumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.

Illumina (ILMN) shares hit a 52-week high after being added to the S&P 500 Equal Weighted Index. The company announced a $300M note offering, strong earnings, and raised full-year guidance. Analysts increased price targets, citing sustainable earnings and clinical sequencing demand. The stock's rise is driven by index inclusion, debt refinancing, and upgraded guidance, with future growth expected from its sequencer business model.

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.